Search Results

ABIONYX Pharma acknowledges that the Phase 3 AEGIS-II study evaluating the efficacy and safety of CSL Behring’s human-plasma-derived apoA-I, CSL112, compared to placebo in reducing the risk of major adverse cardiovascular events in patients following an acute myocardial infarction, did not meet its primary efficacy endpoint of MACE reduction at 90 days.

Biognosys, a leader in next-generation proteomics services, software and kits for life sciences research and drug development, announced the launch of the novel, proprietary P2 Plasma Enrichment method for single-well, single particle-type enrichment with market leading performance and sensible, superior economics.

Global “Plasma Fractionation Market” in terms of revenue was estimated to be worth $4.2 Bn in 2023 and is poised to reach $8.9 Bn by 2031, propelling at a CAGR of 10.1% from 2024 to 2031.

Terumo Blood and Cell Technologies, a medical technology company, recently received U.S. Food and Drug Administration 510 clearance for the Rika Plasma Donation System™ with the iNomi™ Nomogram.

US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.